12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ISIS-APOCIIIRx: Phase II data

A double-blind Phase II trial in 11 Type II diabetics with high triglyceride levels (200-500 mg/dL) showed that once-weekly 300 mg subcutaneous ISIS-APOCIIIRx met the primary endpoint of reducing APOCIII protein levels from baseline to week 13 vs. placebo. Specifically, ISIS-APOCIIIRx reduced APOCIII protein levels by 88% vs. placebo (p<0.03). Compared to placebo, ISIS-APOCIIIRx also significantly reduced fasting plasma triglyceride...

Read the full 279 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >